A Phase 1/2 interventional study of Cannabidiol Oral Solution in Seizures, sponsored by INSYS Therapeutics Inc. Completed at 10 sites in United States. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2017-06-23.
Sponsored by INSYS Therapeutics Inc · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing cannabidiol in Seizures — 2 open to participants now, 2 under way, none of them phase 3. Cannabidiol · Seizures.
Among the 13 studies testing cannabidiol in Seizures, this one is the 7th largest by enrollment, is one of 3 that started in 2015, is the only one in phase 1/2, and was the 2nd registered.
766 studies on the registry are indexed under Seizures; 134 are open to participants now.
Browse Seizures studies →2 of the 13 studies testing cannabidiol in Seizures are open now, in 2 countries. Recruiting first, the newest first:
Jazz Pharmaceuticals · Sites in United States
Ages 12–75
Elizabeth Donner · Sites in Canada
Ages 2–18
By country, each count listing its studies:
Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.
This study: 1 Year to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 1 · Phase 3 5 · Phase 4 3
First in 2014; this study’s year is marked. 3 started in 2015.
This study's enrollment of 61 is close to the median of 64 across 519 interventional studies indexed under Seizures.
Median enrollment 61 across the 13 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 13 have an industry lead sponsor. The 6 most frequent:
INSYS Therapeutics Inc is the lead sponsor of 45 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
INSYS Therapeutics Inc has 2 studies filed under Seizures — fewer than ten, so there is no comparison to draw.
1 of the studies testing cannabidiol in Seizures that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07233239Jazz PharmaceuticalsA Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures | 2027-11-29 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing cannabidiol in Seizures, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 1/2, open-label trial designed to assess the pharmacokinetics, safety, tolerability, and preliminary efficacy of 3 multiple ascending doses of Cannabidiol Oral Solution in a sequential fashion.
Participants will be pediatric (aged 1-17, inclusive), experiencing treatment-resistant seizures, and satisfy all inclusion/exclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low Dose \[10 milligrams/kilogram/day (mg/kg/day)\] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 5 mg/kg in the morning on Day 1 followed by total dose of 10 mg/kg/day (5 mg/kg in the morning and 5 mg/kg in the evening) on Days 4 to 10.
Drug: Cannabidiol Oral Solution
Mid Dose \[20 mg/kg/day\] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 10 mg/kg in the morning on Day 1 followed by total dose of 20 mg/kg/day (10 mg/kg in the morning and 10 mg/kg in the evening) on Days 4 to 10.
Drug: Cannabidiol Oral Solution
High Dose \[40 mg/kg/day\] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 20 mg/kg in the morning on Day 1 followed by total dose of 40 mg/kg/day (20 mg/kg in the morning and 20 mg/kg in the evening) on Days 4 to 10.
Drug: Cannabidiol Oral Solution
An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
Maximum Plasma Concentration (Cmax) for Cannabidiol and Metabolite 7-hydroxy (7-OH) Cannabidiol
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hours post-dose.
Time frame: Day 1 at age-specific times
Cmax for Cannabidiol and Metabolite 7-OH Cannabidiol
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.
Time frame: Day 10 at age-specific times
Dose Normalized Cmax (Cmax/D) for Cannabidiol and Metabolite 7-OH Cannabidiol
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17: Day 1 pre-dose and at 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hours post-dose.
Time frame: Day 1 at age-specific times
Cmax/D for Cannabidiol and Metabolite 7-OH Cannabidiol
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.
Time frame: Day 10 at age-specific times
Time to Cmax (Tmax) for Cannabidiol and Metabolite 7-OH Cannabidiol
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose.
Time frame: Day 1 at age-specific times
Time to Cmax (Tmax) for Cannabidiol and Metabolite 7-OH Cannabidiol
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.
Time frame: Day 10 at age-specific times
Half Life (t1/2) for Cannabidiol and Metabolite 7-OH Cannabidiol for Participants ≥2 Years of Age
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.
Time frame: Day 1 at age-specific times
Elimination Rate (Lambda-z [λz]) for Cannabidiol and Metabolite 7-OH Cannabidiol for Participants ≥2 Years of Age
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.
Time frame: Day 1 at age-specific times
Oral Clearance (CL/F) for Cannabidiol for Participants ≥2 Years of Age
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.
Time frame: Day 1 at age-specific times
Volume of Distribution (Vz/F) of Cannabidiol for Participants ≥2 Years of Age
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.
Time frame: Day 1 at age-specific times
Area Under the Plasma-Concentration Time Curve From 0 to 12 Hours Post-dose [AUC(0-12)] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose.
Time frame: Day 1 at age-specific times
Dose Normalized AUC(0-12) [AUC (0-12)/D] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose.
Time frame: Day 1 at age-specific times
AUC From Time 0 to the Last Quantifiable Concentration [AUC(0-last)] on Day 1 for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1 for Participants ≥2 Years of Age
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.
Time frame: Day 1 at age-specific times
AUC From Time 0 to Infinity [AUC(0-inf)] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1 for Participants ≥2 Years of Age
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.
Time frame: Day 1 at age-specific times
Dose Normalized AUC(0-inf) [AUC(0-inf)/D] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1 for Participants ≥2 Years of Age
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.
Time frame: Day 1 at age-specific times
Metabolite (7-OH Cannabidiol) to Parent (Cannabidiol) Ratio for Cmax [MRCmax] on Day 1
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose. MRCmax was adjusted for molecular weight differences between cannabidiol (341.46) and 7-OH cannabidiol (330.46).
Time frame: Day 1 at age-specific times
MRCmax on Day 10
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose. MRCmax was adjusted for molecular weight differences between cannabidiol (341.46) and 7-OH cannabidiol (330.46).
Time frame: Day 10 at age-specific times
Metabolite to Parent Ratio for AUC(0-inf) [MRAUC(0-inf)] on Day 1 for Participants ≥2 Years of Age
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis. MRAUC(0-inf) was adjusted for molecular weight differences between cannabidiol (341.46) and 7-OH cannabidiol (330.46).
Time frame: Day 1 at age-specific times
Metabolite to Parent Ratio for AUC(0-12) [MRAUC(0-12)] on Day 1
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose. MRAUC(0-12) was adjusted for molecular weight differences between cannabidiol (341.46) and 7-OH cannabidiol (330.46).
Time frame: Day 1 at age-specific times
Metabolite to Parent Ratio for AUC(0-12) [MRAUC(0-12)] on Day 10
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose. MRAUC(0-12) was adjusted for molecular weight differences between cannabidiol (341.46) and 7-OH cannabidiol (330.46).
Time frame: Day 10 at age-specific times
AUC(0-12) for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 10
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.
Time frame: Day 10 at age-specific times
Dose Normalized AUC(0-12) [AUC (0-12)/D] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 10
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.
Time frame: Day 10 at age-specific times
Minimum Plasma Concentration (Cmin) for Cannabidiol and Metabolite 7-OH Cannabidiol
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.
Time frame: Day 10 at age-specific times
Average Plasma Concentration (Cavg) for Cannabidiol and Metabolite 7-OH Cannabidiol
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.
Time frame: Day 10 at age-specific times
Accumulation Ratio for Cmax (RCmax) on Day 10 for Cannabidiol and Metabolite 7-OH Cannabidiol
RCmax is the ratio of Cmax at Day 10 compared to Cmax at Day 1. Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.
Time frame: Day 10 at age-specific times
Accumulation Ratio for AUC(0-12) [RAUC(0-12)] on Day 10 for Cannabidiol and Metabolite 7-OH Cannabidiol
RAUC(0-12) is the ratio of AUC(0-12) at Day 10 compared to AUC(0-12) at Day 1. Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.
Time frame: Day 10 at age-specific times
Time Linearity Index for Cannabidiol and Metabolite 7-OH Cannabidiol in Participants ≥2 Years of Age
Time linearity index is calculated as the ratio of AUC(0-12) on Day 10/AUC\[0-inf\] on Day 1. Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.
Time frame: Day 1 and Day 10
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product. It does not necessarily have a causal relationship with this treatment. A TEAE was defined as any event not present prior to the initiation of the treatment or any event already present that worsens. Any laboratory (clinical chemistry, hematology, urinalysis), 12-lead electrocardiograms, vital signs (temperature, blood pressure, pulse rate, respiratory rate) and physical examination findings deemed by the investigator to be clinically significant were captured as AEs. A SAE is any untoward medical occurrence that results in death, is life-threatening, requires the participant be at a risk of death at the time of the event, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect, or other serious event that requires medical or surgical intervention.
Time frame: From the first dose of study drug up to Day 17
Clinical Global Impression of Improvement (CGI-I) Assessment
The CGI-I was completed by the parents/caregivers and the investigator and was used to assess participants global status of their condition on Day 11 using a 7-point scale, where 1=very much improved and 7=very much worse since the initiation of treatment.
Time frame: Day 11
Change From Baseline in Clinical Global Impression of Severity (CGI-S) Assessment
The CGI-S was completed by the parents/caregivers and the Investigator and was used to rate participant's mental illness status at Baseline (Screening) and Day 11 using a 7-point scale, where 1=normal, not mentally ill, and 7=among the most extremely mentally ill participants. This rating is based upon observed and reported symptoms, behavior, and function in the past seven days. The change in CGI-S score at Day 11 relative to Baseline is reported. A negative change from Baseline indicates improvement (decreased severity in illness).
Time frame: Baseline and Day 11
Change From Baseline in Daily Seizure Activity
The specific number of tonic and atonic seizures per study day were recorded in a diary. The change in number of seizures at Day 11 relative to Baseline is reported. A negative change from Baseline indicates an improvement based on Daily Seizure Activity.
Time frame: Baseline and Day 11
Number of Participants With Suicide Related Thoughts and Behaviors Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
The C-SSRS captured the occurrence, severity, and frequency of suicide related thoughts and behaviors at Day 11. The C-SSRS was only used for participants ≥ 7 years of age. The number of participants with results of "Yes" for Suicidal Ideation (Wish to be Dead and Non-Specific Active Suicidal Thoughts) and Suicidal Behavior (Actual Attempt, Interrupted Attempt, Aborted Attempt, Preparatory Acts or Behavior, and Suicidal Behavior) are reported.
Time frame: Day 11
| Milestone | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Started | 20 | 20 | 21 |
| Completed | 20 | 20 | 21 |
| Not completed | 0 | 0 | 0 |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hours post-dose.
| nanograms/milliliter (ng/mL) | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Cannabidiol | 59.03 ± 99.98 | 110.5 ± 142.3 | 256.9 ± 351.9 |
| 7-OH Cannabidiol | 28.71 ± 26.72 | 61.89 ± 72.88 | 140.9 ± 210.0 |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.
| ng/mL | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Cannabidiol | 119.6 ± 105.0 | 220.0 ± 294.7 | 426.8 ± 327.7 |
| 7-OH Cannabidiol | 79.38 ± 40.82 | 136.6 ± 140.9 | 286.1 ± 201.9 |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17: Day 1 pre-dose and at 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hours post-dose.
| ng/mL/(mg/kg) | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Cannabidiol | 11.72 ± 19.89 | 10.77 ± 13.97 | 13.25 ± 18.07 |
| 7-OH Cannabidiol | 5.737 ± 5.330 | 5.990 ± 7.011 | 7.286 ± 10.91 |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.
| ng/mL/(mg/kg) | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Cannabidiol | 23.79 ± 20.46 | 21.16 ± 28.40 | 21.40 ± 16.38 |
| 7-OH Cannabidiol | 15.82 ± 7.928 | 13.10 ± 13.06 | 14.39 ± 10.26 |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose.
| hours (h) | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Cannabidiol | 2.58 (1.02 to 8.00) | 4.00 (1.00 to 8.08) | 3.15 (1.00 to 24.02) |
| 7-OH Cannabidiol | 2.55 (1.00 to 6.08) | 4.00 (1.00 to 11.95) | 3.07 (1.00 to 12.05) |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.
| h | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Cannabidiol | 2.99 (1.00 to 4.25) | 2.00 (0.00 to 6.00) | 3.00 (0.00 to 6.02) |
| 7-OH Cannabidiol | 2.08 (1.00 to 4.08) | 2.03 (1.00 to 6.05) | 2.03 (0.00 to 5.90) |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.
| h | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Cannabidiol | 31.31 ± 23.46 | 33.48 ± 14.97 | 21.58 ± 10.50 |
| 7-OH Cannabidiol | 19.71 ± 7.640 | 31.84 ± 24.28 | 14.77 ± 4.354 |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.
| 1/h | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Cannabidiol | 0.02969 ± 0.01386 | 0.02836 ± 0.02340 | 0.03949 ± 0.01976 |
| 7-OH Cannabidiol | 0.04053 ± 0.01557 | 0.03276 ± 0.01985 | 0.05123 ± 0.01711 |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.
| Liters (L)/h/kg | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Oral Clearance (CL/F) for Cannabidiol for Participants ≥2 Years of Age | 29.78 ± 15.96 | 21.10 ± 23.04 | 31.29 ± 30.43 |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.
| L/kg | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Volume of Distribution (Vz/F) of Cannabidiol for Participants ≥2 Years of Age | 1021 ± 609.1 | 930.8 ± 1034 | 982.6 ± 1119 |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose.
| ng*h/mL | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Cannabidiol | 173.9 ± 179.6 | 507.1 ± 687.7 | 914.5 ± 1155 |
| 7-OH Cannabidiol | 124.4 ± 80.18 | 329.8 ± 402.9 | 646.7 ± 886.3 |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose.
| ng*h/mL | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Cannabidiol | 34.60 ± 35.48 | 49.23 ± 66.68 | 47.13 ± 59.38 |
| 7-OH Cannabidiol | 24.88 ± 15.93 | 31.77 ± 38.00 | 33.39 ± 45.94 |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.
| ng*h/mL | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Cannabidiol | 250.0 ± 217.1 | 692.5 ± 826.9 | 1355 ± 1447 |
| 7-OH Cannabidiol | 212.2 ± 112.1 | 544.9 ± 526.6 | 1221 ± 1296 |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.
| ng*h/mL | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Cannabidiol | 270.1 ± 256.7 | 1140 ± 1118 | 1584 ± 1709 |
| 7-OH Cannabidiol | 229.3 ± 122.3 | 704.1 ± 627.8 | 1354 ± 1428 |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.
| ng*h/mL/(mg/kg) | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Cannabidiol | 53.64 ± 50.04 | 111.8 ± 111.2 | 83.10 ± 87.93 |
| 7-OH Cannabidiol | 46.07 ± 24.63 | 68.43 ± 62.34 | 70.34 ± 73.66 |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose. MRCmax was adjusted for molecular weight differences between cannabidiol (341.46) and 7-OH cannabidiol (330.46).
| ratio | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Metabolite (7-OH Cannabidiol) to Parent (Cannabidiol) Ratio for Cmax [MRCmax] on Day 1 | 0.8935 ± 0.5543 | 0.9328 ± 0.8332 | 0.8081 ± 0.4849 |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose. MRCmax was adjusted for molecular weight differences between cannabidiol (341.46) and 7-OH cannabidiol (330.46).
| ratio | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| MRCmax on Day 10 | 0.7717 ± 0.3960 | 0.8230 ± 0.3880 | 0.7657 ± 0.4179 |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis. MRAUC(0-inf) was adjusted for molecular weight differences between cannabidiol (341.46) and 7-OH cannabidiol (330.46).
| ratio | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Metabolite to Parent Ratio for AUC(0-inf) [MRAUC(0-inf)] on Day 1 for Participants ≥2 Years of Age | 0.9099 ± 0.5173 | 0.9459 ± 0.4874 | 0.9538 ± 0.4370 |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 1 at 2, 4, 8, 12 hours post-dose; Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose. MRAUC(0-12) was adjusted for molecular weight differences between cannabidiol (341.46) and 7-OH cannabidiol (330.46).
| ratio | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Metabolite to Parent Ratio for AUC(0-12) [MRAUC(0-12)] on Day 1 | 0.9309 ± 0.5229 | 0.9793 ± 0.7147 | 0.9085 ± 0.5075 |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose. MRAUC(0-12) was adjusted for molecular weight differences between cannabidiol (341.46) and 7-OH cannabidiol (330.46).
| ratio | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Metabolite to Parent Ratio for AUC(0-12) [MRAUC(0-12)] on Day 10 | 0.8795 ± 0.4084 | 0.7866 ± 0.2361 | 0.8700 ± 0.4304 |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.
| ng*h/mL | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Cannabidiol | 581.6 ± 283.4 | 1098 ± 976.4 | 2708 ± 1789 |
| 7-OH Cannabidiol | 513.4 ± 269.0 | 832.8 ± 675.2 | 2165 ± 1405 |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.
| ng*h/mL/(mg/kg) | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Cannabidiol | 115.8 ± 55.32 | 106.0 ± 94.64 | 135.7 ± 89.17 |
| 7-OH Cannabidiol | 102.2 ± 53.01 | 80.19 ± 63.53 | 108.7 ± 70.76 |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.
| ng/mL | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Cannabidiol | 19.97 ± 8.798 | 41.67 ± 25.41 | 118.3 ± 75.82 |
| 7-OH Cannabidiol | 21.82 ± 13.23 | 34.11 ± 23.99 | 108.7 ± 70.87 |
Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.
| ng/mL | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Cannabidiol | 48.56 ± 23.58 | 91.38 ± 80.92 | 225.7 ± 149.3 |
| 7-OH Cannabidiol | 42.94 ± 22.54 | 69.37 ± 56.09 | 180.4 ± 117.1 |
RCmax is the ratio of Cmax at Day 10 compared to Cmax at Day 1. Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.
| ratio | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Cannabidiol | 5.535 ± 5.551 | 4.454 ± 4.466 | 7.488 ± 11.93 |
| 7-OH Cannabidiol | 3.823 ± 2.730 | 3.996 ± 3.544 | 5.788 ± 6.028 |
RAUC(0-12) is the ratio of AUC(0-12) at Day 10 compared to AUC(0-12) at Day 1. Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 1 to \<2 years: Day 10 pre-dose and at 2, 4, 8 and 12 hours post-dose; Participants ages 2 to \<6 years: Day 10 pre-dose and at 1, 2, 3, 4, 8, 12 and 24 hours post-dose; Participants ages 6 to ≤17 years: Day 10 pre-dose and at 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.
| ratio | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Cannabidiol | 5.434 ± 3.625 | 5.489 ± 4.633 | 9.376 ± 15.11 |
| 7-OH Cannabidiol | 4.865 ± 2.748 | 4.524 ± 3.338 | 7.541 ± 7.187 |
Time linearity index is calculated as the ratio of AUC(0-12) on Day 10/AUC\[0-inf\] on Day 1. Serial blood sample collection times for pharmacokinetic (PK) analysis were based on the participant's age as follows: Participants ages 2 to \<6 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24 and 48 hours post-dose; Participants ages 6 to ≤17 years: Day 1 pre-dose and at 1, 2, 3, 4, 8, 12, 16, 24, 36, 48 and 72 hours post-dose; Participants ages 1 to \<2 years were not included in this analysis.
| ratio | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Cannabidiol | 3.211 ± 2.048 | 2.628 ± 2.276 | 4.201 ± 4.990 |
| 7-OH Cannabidiol | 2.500 ± 0.9365 | 1.821 ± 1.162 | 3.045 ± 2.260 |
An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product. It does not necessarily have a causal relationship with this treatment. A TEAE was defined as any event not present prior to the initiation of the treatment or any event already present that worsens. Any laboratory (clinical chemistry, hematology, urinalysis), 12-lead electrocardiograms, vital signs (temperature, blood pressure, pulse rate, respiratory rate) and physical examination findings deemed by the investigator to be clinically significant were captured as AEs. A SAE is any untoward medical occurrence that results in death, is life-threatening, requires the participant be at a risk of death at the time of the event, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect, or other serious event that requires medical or surgical intervention.
| Participants | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| TEAE | 13 | 9 | 17 |
| SAE | 0 | 1 | 2 |
The CGI-I was completed by the parents/caregivers and the investigator and was used to assess participants global status of their condition on Day 11 using a 7-point scale, where 1=very much improved and 7=very much worse since the initiation of treatment.
| scores on a scale | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Parents/Caregivers | 2.1 ± 1.02 | 2.4 ± 0.82 | 2.3 ± 1.15 |
| Investigator | 2.7 ± 0.92 | 2.5 ± 0.94 | 2.9 ± 0.91 |
The CGI-S was completed by the parents/caregivers and the Investigator and was used to rate participant's mental illness status at Baseline (Screening) and Day 11 using a 7-point scale, where 1=normal, not mentally ill, and 7=among the most extremely mentally ill participants. This rating is based upon observed and reported symptoms, behavior, and function in the past seven days. The change in CGI-S score at Day 11 relative to Baseline is reported. A negative change from Baseline indicates improvement (decreased severity in illness).
| scores on a scale | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Parents/Caregivers | -1.7 ± 2.08 | -2.2 ± 2.04 | -1.8 ± 1.64 |
| Investigator | -1.1 ± 1.27 | -0.7 ± 1.15 | -0.7 ± 1.23 |
The specific number of tonic and atonic seizures per study day were recorded in a diary. The change in number of seizures at Day 11 relative to Baseline is reported. A negative change from Baseline indicates an improvement based on Daily Seizure Activity.
| number of seizures per day | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Number of Tonic Seizures | -0.8 ± 1.55 | -0.8 ± 1.59 | -2.9 ± 7.69 |
| Number of Atonic Seizures | -0.2 ± 0.98 | -0.1 ± 0.28 | 0.0 ± 0.00 |
The C-SSRS captured the occurrence, severity, and frequency of suicide related thoughts and behaviors at Day 11. The C-SSRS was only used for participants ≥ 7 years of age. The number of participants with results of "Yes" for Suicidal Ideation (Wish to be Dead and Non-Specific Active Suicidal Thoughts) and Suicidal Behavior (Actual Attempt, Interrupted Attempt, Aborted Attempt, Preparatory Acts or Behavior, and Suicidal Behavior) are reported.
| Participants | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| Suicide Ideation | 0 | 0 | 0 |
| Suicide Behavior | 0 | 0 | 0 |
Collected over From the first dose of study drug to 7 days after the last dose of study drug (up to Day 17). Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | 0/20 (0%) | 0/20 (0%) | 13/20 (65%) |
| Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | 0/20 (0%) | 1/20 (5%) | 9/20 (45%) |
| High Dose Cannabidiol Oral Solution [40 mg/kg/Day] | 0/21 (0%) | 2/21 (9.5%) | 17/21 (81%) |
| Event | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| ThrombophlebitisVascular disorders | 0/20 | 1/20 | 0/21 |
| ApnoeaRespiratory, thoracic and mediastinal disorders | 0/20 | 0/20 | 1/21 |
| Drug eruptionSkin and subcutaneous tissue disorders | 0/20 | 0/20 | 1/21 |
| Event | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/20 | 2/20 | 7/21 |
| SomnolenceNervous system disorders | 3/20 | 3/20 | 7/21 |
| AnaemiaBlood and lymphatic system disorders | 2/20 | 5/20 | 4/21 |
| FlatulenceGastrointestinal disorders | 0/20 | 2/20 | 3/21 |
| Psychomotor hyperactivityNervous system disorders | 0/20 | 2/20 | 3/21 |
| Abdominal pain upperGastrointestinal disorders | 2/20 | 1/20 | 0/21 |
| VomitingGastrointestinal disorders | 2/20 | 1/20 | 0/21 |
| Catheter site pruritusGeneral disorders | 0/20 | 2/20 | 1/21 |
| Decreased appetiteMetabolism and nutrition disorders | 2/20 | 0/20 | 1/21 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/20 | 2/20 | 0/21 |
Safety Analysis Population (SAF), all participants who received ≥1 dose of the investigational product.
| Age, Continuous(years) | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] | Total |
|---|---|---|---|---|
| Mean | 7.5 ± 5.32 | 7.7 ± 5.17 | 7.8 ± 5.39 | 7.6 ± 5.21 |
| Age, Customized(Participants) | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] | Total |
|---|---|---|---|---|
| Infants = 1 to <2 years | 5 | 5 | 5 | 15 |
| Children = 2 to <12 years | 9 | 9 | 10 | 28 |
| Adolescents = 12 to ≤17 years | 6 | 6 | 6 | 18 |
| Sex: Female, Male(Participants) | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] | Total |
|---|---|---|---|---|
| Female | 10 | 7 | 11 | 28 |
| Male | 10 | 13 | 10 | 33 |
| Region of Enrollment(Participants) | Low Dose Cannabidiol Oral Solution [10 mg/kg/Day] | Mid Dose Cannabidiol Oral Solution [20 mg/kg/Day] | High Dose Cannabidiol Oral Solution [40 mg/kg/Day] | Total |
|---|---|---|---|---|
| United States | 20 | 20 | 21 | 61 |
Ran from Apr 2015 to primary completion in May 2016, 12 months.
Results were first posted in Jun 2017, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol